BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company commercializing a
proprietary biomedical signal processing platform designed to
improve signal fidelity and uncover the full range of ECG and
intra-cardiac signals, today appointed Mr. Anthony (‘Tony’) Zook to
its Board of Directors.
Mr. Zook brings to the Company a wealth of commercialization
experience in the life science industry gained primarily through
his career at AstraZeneca Plc [LON:AZN]. Mr. Zook held several
executive positions at AstraZeneca, including Executive Vice
President of Global Commercial Operations from 2010 to 2013,
President and Chief Executive Officer of the North American
division from 2007 to 2010 and President of Medimmune, the
wholly-owned biologics division of AstraZeneca, from 2008 to 2010.
Under Mr. Zook’s leadership, AstraZeneca commercialized ten
blockbuster brands, each over $1 billion in sales. Along with the
CEO, CFO, and Head of R&D, Mr. Zook sat on the Portfolio
Investment Board (PIB), which set and approved the overall strategy
for Research and Development and allocated resources by therapeutic
area. Mr. Zook served or continues to serve on several boards,
including the boards of AltheRx, Inhibikase, Rib-X Pharmaceuticals,
the National Pharmaceutical Council, PhRMA, the Pennsylvania
Division of the American Cancer Society and his alma mater,
Frostburg State University. Mr. Zook earned a B.S. degree from
Frostburg State University and an A.A. degree in chemical
engineering from Pennsylvania State University.
“The rapid progress made by our subsidiary ViralClear
Pharmaceuticals, Inc. would not have been possible without Tony’s
expert guidance and leadership. We are delighted that Tony accepted
the offer to join the Board of the parent company, a role that will
allow him to assist us in the development of our pharmaceutical
business,” stated Kenneth L. Londoner, Chairman, and CEO of BioSig
Technologies, Inc.
“The ongoing and briskly progressing Phase II clinical trial of
ViralClear could be an important inflection point in the
development of ViralClear. From working to execute the trial and
collect patient data, to preparing for the next steps, we have an
ambitious plan in front of us. I’m pleased to provide my executive
and operating expertise to support the Company’s goals and
objectives,” commented Mr. Zook.
ViralClear recently opened patient enrollment in six hospitals
across the country, including three Mayo Clinic sites and St.
David’s South Austin Medical Center in Austin, TX. The Company
partnered with Catalent, the leading global provider of advanced
delivery technologies, development, and manufacturing solutions for
drugs, biologics, cell and gene therapies, and consumer health
products, to work on the development of a potential treatment for
adults with advanced Coronavirus Disease 2019 (COVID-19).
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP(tm) System, is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
About Viral Clear Pharmaceuticals and Merimepodib
(MMPD) BioSig’s subsidiary, ViralClear Pharmaceuticals,
Inc., is seeking to develop a novel pharmaceutical called
merimepodib to treat patients with COVID-19. Merimepodib is
intended to be orally administered, and has demonstrated
broad-spectrum in vitro antiviral activity, including strong
activity against SARS-CoV-2 in cell cultures. Merimepodib was
previously in development as a treatment for chronic hepatitis C
and psoriasis by Vertex Pharmaceuticals Incorporated (Vertex), with
12 clinical trials (7 in phase 1 and 5 in phase 2) with over 400
subjects and patients and an extensive preclinical safety, package
was completed. A manuscript titled, “The IMPDH inhibitor
merimepodib provided in combination with the adenosine analog
remdesivir reduces SARS-CoV-2 replication to undetectable levels in
vitro”, was submitted to an online peer-reviewed life sciences
journal. This manuscript is authored by Natalya Bukreyeva, Rachel
A. Sattler, Emily K. Mantlo, John T. Manning, Cheng Huang and
Slobodan Paessler of the UTMB Galveston National Laboratory and Dr.
Jerome Zeldis , a board member of BioSig who is helping oversee
ViralClear, as a corresponding author. This article highlights
preclinical data generated under contract with Galveston National
Laboratory at The University of Texas Medical Branch.
Forward-looking StatementsThis press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024